AIDX (20/20 Biolabs) Long-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AIDX 20/20 Biolabs Inc AIDX
6 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is 20/20 Biolabs Long-Term Debt?

20/20 Biolabs AIDX -0.23% 6 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

20/20 Biolabs's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

20/20 Biolabs's quarterly Long-Term Debt increased from Sep. 2025 ($0.45 Mil) to Dec. 2025 ($0.62 Mil) but then declined from Dec. 2025 ($0.62 Mil) to Mar. 2026 ($0.00 Mil).

20/20 Biolabs's annual Long-Term Debt declined from Dec. 2023 ($0.23 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.62 Mil).

20/20 Biolabs  (NAS:AIDX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

20/20 Biolabs Long-Term Debt Related Terms

20/20 Biolabs Long-Term Debt Historical Data

* Premium members only.

The historical data trend for 20/20 Biolabs's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

20/20 Biolabs Long-Term Debt Chart

20/20 Biolabs Annual Data
Trend Dec23 Dec24 Dec25
Long-Term Debt
0.23 0.00 0.62

20/20 Biolabs Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.45 0.62 0.00
AIDX
6GF Score
20/20 Biolabs Inc AIDX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
20/20 Biolabs (AIDX) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is 20/20 Biolabs' Long-Term Debt too high?
20/20 Biolabs' current Long-Term Debt is $0.00 Mil. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' Long-Term Debt compare to STME and TRIB?
20/20 Biolabs' Long-Term Debt of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. 20/20 Biolabs's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

20/20 Biolabs Business Description

Address 15810 Gaither Road, Suite 235, Gaithersburg, MD, USA, 20877
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score

Get the complete analysis for AIDX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price